PubMed Health⌕ Search

Biomedical subjects

H Sigurdsson

Publications and source records attributed to H Sigurdsson.

47 records · Page 3Linked to original sources
PubMed1989

A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma.

The use of tamoxifen is expanding in its application in the treatment of breast carcinoma, and proposed prophylactic use. Tamoxifen in high dosage and in some reports at conventional dosage is associated with ocular toxicity. This study in a single blind fashion examined 79 patients receiving tamoxifen for varying treatment durations at conventional dosage and 115 patients not receiving tamoxifen. No ocular toxicity was found. Further follow up studies are required to ensure no toxicity develops in patients receiving high cumulative dosage on conventional therapy.

Aged↗
PubMed1989

Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group.

From January 1981 to February 1986, a total of 240 patients with primary, malignancy-grade III or IV soft tissue sarcoma were entered into an adjuvant chemotherapy multicenter trial conducted by the Scandinavian Sarcoma Group (SSG). Of these patients, 181 were evaluable. The tumor was located in the extremities in 155 patients. After radical surgery (wide and compartmental) the patients were randomized to treatment with single-agent doxorubicin 60 mg/m2 administered as an intravenous (IV) bolus once a month for 9 months (group 1, n = 77) or to control (group 2, n = 77). If the surgical procedure was marginal, the patients initially received postoperative radiotherapy, followed by doxorubicin (group 3, n = 16) or control (group 4, n = 11). The control groups did not receive any adjuvant chemotherapy. Adjuvant therapy was initiated within 6 weeks of surgery (group 1) or within 10 weeks of surgery for patients receiving postoperative radiotherapy (group 3). With a median follow-up of 40 months, there was no significant difference between the four treatment groups in overall survival (group 1, 75%; group 2, 70%; group 3, 69%; group 4, 73%), disease-free survival (group 1, 62%; group 2, 56%; group 3, 62%; group 4, 64%), or local tumor control (group 1, 92%; group 2, 92%; group 3, 87%; group 4, 90%). The conclusions were the same whether the total group or evaluable patients only were included in the analysis. The local recurrence rate for patients undergoing radical surgery was 8% and for patients undergoing marginal surgery followed by radiotherapy was 12%. This study indicates that the use of single-agent doxorubicin as postoperative adjuvant chemotherapy has no significant clinical benefit in patients with high-grade soft tissue sarcoma.

Adolescent↗
PubMed1988

Vitrectomy for diabetic eye disease.

Thirty four eyes which underwent vitrectomy because of diabetic proliferative retinopathy were reviewed. The overall success rate of the operation was 62%. Excluding table top retinal detachments, which all did badly, the success rate was 72%. Grading by ultrasound was found to be helpful in; (a) planning surgical approach, (b) assessing visual outcome. The most common late complication was cataract. Extracapsular cataract extraction with implantation was found to be successful in these cases.

Adult↗
PubMed1988

Follicular conjunctivitis on Dipivefrin therapy for glaucoma.

Dipivefrin (Propine) is an effective ocular hypotensive agent. Follicular conjunctivitis has been observed in an unexpectedly high incidence of glaucoma patients on this topical therapy. Severe discomfort was experienced by a few patients. Follicles resolved after withdrawal of this medication, but may persist or recur upon subsequent treatment with other adrenaline related compounds. Regular examination of the conjunctiva is recommended for early signs of this side-effect, which initially may be symptom free.

Adult↗
PubMed1986

Weekly-dose doxorubicin (WDA) in advanced breast cancer.

Doxorubicin in a weekly fixed dose of 20 mg as i.v. bolus (WDA) was given to 48 patients with mostly pretreated progressing breast cancer. The response rate (CR + PR) was 9/48 (19%), and a further 16 (33%) of the patients achieved stable disease. Myelosuppression was mild and without clinical significance. Other side effects, particularly nausea, vomiting and hair loss were also relatively mild. Cardiac toxicity, however, was seen in six patients. Five of these six patients were previously treated with mitoxantrone or combination chemotherapy containing doxorubicin. Median response duration was 10+ months for responders and 11+ months in patients who had stable disease. It is concluded that weekly-dose doxorubicin has a favourable profile with a low frequency of side effects and that this treatment is an alternative to other cancer chemotherapy in breast cancer, especially when not only CR and PR but even stabilization of disease is considered of benefit to the patient.

Adult↗